The Scan by 2 Minute Medicine®: celebrity whole-body MRI craze floods clinics, cruise ship hantavirus outbreak prompts global tracing, “Ozempic personality” raises new questions, and TikTok’s “cortisol face” trend drives endocrine workups

Celebrity body scan craze floods clinics as radiologists push back

Endorsements from Kim Kardashian, Paris Hilton, and Kris Jenner have made whole-body MRI one of 2026’s fastest-growing consumer health trends, with services like Prenuvo marketing their AI-enhanced screening as a way to detect over 500 conditions in asymptomatic adults for up to $2,499 out of pocket. A 2026 analysis in the Journal of Magnetic Resonance Imaging found that applying whole-body MRI to average-risk populations diverges sharply from conventional screening principles given very low pre-test probability of clinically significant findings. Population-level data show that up to 94% of scanned asymptomatic patients have at least one radiologic abnormality, while the vast majority of those findings are benign and carry no clinical consequence. A spring 2026 evidence review found that only 14.7% of social media posts about whole-body MRI mentioned potential harms, while 87% were overtly promotional. Incidental finding rates approach 30 to 40% in some organ-specific studies, frequently triggering biopsies, specialist referrals, and follow-up imaging with limited clinical yield. One German cohort found whole-body MRI associated with 11.6% higher two-year outpatient costs, driven primarily by workup of ultimately benign incidentalomas. Prenuvo’s internal data report a 2.2% rate of biopsy-confirmed cancer diagnoses across its scanned population, a figure the company cites in its consumer marketing. The Canadian Association of Radiologists issued a policy statement calling the practice not clinically responsible and not equitable for average-risk individuals, citing downstream burden on publicly funded imaging infrastructure. Primary care physicians are increasingly fielding consults from patients who paid out of pocket and returned with lists of ambiguous findings requiring interpretation. Whether evidence-based protocols or payer criteria will define appropriate use of whole-body MRI in asymptomatic populations remains unresolved.

Andes hantavirus aboard cruise ship MV Hondius prompts global contact tracing across 32 countries

An outbreak of Andes virus infection aboard the Dutch-flagged expedition cruise ship MV Hondius, which departed Ushuaia, Argentina in April 2026, resulted in 11 confirmed cases and 3 deaths, with the CDC coordinating repatriation of 18 American passengers to the University of Nebraska Medical Center for a 42-day public health monitoring period. A correspondence in the New England Journal of Medicine described the clinical course in detail, noting that standard respiratory pathogen panels were negative throughout and diagnosis required pan-hantavirus RT-PCR, with Andes virus confirmed by sequencing at the National Institute for Communicable Diseases in South Africa. Andes virus is the only known hantavirus with documented person-to-person transmissibility, and the WHO disease outbreak notice reported over 600 contacts identified across 32 countries under active or self-monitoring as of late May. Illness onset among confirmed cases was characterized by fever, gastrointestinal symptoms, and rapid progression to pneumonia, acute respiratory distress syndrome, and shock. The exact transmission mode aboard the ship, whether through close respiratory contact, contaminated surfaces, or a combination, remains under investigation. WHO clarified that the virus does not exhibit transmission dynamics consistent with highly transmissible airborne pathogens such as measles. Any returning traveler presenting with severe respiratory illness, febrile onset, and negative standard panels after travel through South America should have hantavirus cardiopulmonary syndrome in the differential. The 42-day monitoring window reflects uncertainty around the incubation period for person-to-person Andes virus transmission, which is longer than most travel medicine protocols account for. Biotech markets briefly responded, with Moderna and Novavax shares spiking when the WHO identified the causative agent, before receding as analysts noted the low risk of broader community spread. Moderna has active preclinical research on a hantavirus vaccine platform.

“Ozempic personality” meets new genetic data on GLP-1 non-response

Clinicians are increasingly encountering patients on GLP-1 receptor agonists who report emotional flatness, reduced libido, and diminished interest in previously enjoyable activities — a pattern the Washington Post was among the first major outlets to document, coining the shorthand “Ozempic personality.” Physicians describe the experience as a mild form of anhedonia consistent with dampening of the brain’s dopamine reward pathways, distinct from clinical depression but reported with enough frequency and consistency to draw formal clinical attention. Novo Nordisk has studied semaglutide in over 54,000 participants, and anhedonia is not currently listed as an adverse drug reaction or warning in the prescribing information. Eli Lilly has similarly stated it has no data to share on anhedonia in tirzepatide users. A separate study in Genome Medicine, led by researchers at Stanford Medicine and ETH Zurich, identified variants in the PAM gene carried by approximately 10% of the population that measurably reduce the effectiveness of GLP-1 receptor agonists including semaglutide and liraglutide. PAM-variant carriers produce normal or elevated GLP-1 but experience a blunted downstream signaling effect that cannot be compensated for by dose escalation. As Stanford Medicine reported, because the resistance is specific to the GLP-1 receptor axis, dual-agonist agents like tirzepatide — which also activates GIP receptors,  may partially offset the pharmacogenomic deficit in non-responders. The two findings together present a more complete clinical picture: some patients may experience genuine dopamine-related emotional changes, while others may have a genetic explanation for metabolic plateau that has nothing to do with adherence or lifestyle. Neither manufacturer has published subgroup data on mood outcomes in PAM-variant populations. Whether genetic testing for PAM variants will inform GLP-1 prescribing decisions in future guidelines is an active area of development.

TikTok’s “cortisol face” trend drives a surge of Cushing syndrome workup requests

A TikTok trend in which users attribute facial puffiness and weight gain to chronic stress-induced cortisol elevation, termed “cortisol face”, has driven a notable uptick in patients requesting cortisol testing, a pattern examined in a recent Medical Economics clinical commentary. The trend gained cultural credibility after comedian Amy Schumer was correctly diagnosed with exogenous Cushing’s syndrome in 2024, after online observers noted her facial swelling during a press tour — a case Schumer has since described publicly as a diagnosis that steroid injections for an underlying condition had caused. Endogenous Cushing’s syndrome affects 2 to 3 people per million annually in European population-based studies, and typical day-to-day stress does not raise cortisol to levels capable of producing pathological fat redistribution. True moon facies, a buffalo hump, proximal myopathy, and purple striae require sustained pathologic hypercortisolism, not the ordinary cortisol fluctuations of a stressful week. The Endocrine Society clinical practice guidelines recommend testing only in patients with multiple progressive features of the syndrome, specifying three validated first-line tests: 24-hour urinary free cortisol, late-night salivary cortisol, and the 1-mg overnight dexamethasone suppression test. A University of Colorado endocrinologist noted that random serum cortisol measurements, the tests patients most commonly request based on social media content, are physiologically unreliable and not recommended by any major guideline for screening. Most facial changes driving the trend are attributable to poor sleep, dietary sodium, fluid retention, or normal age-related fat pad redistribution. The false-positive rate of the 1-mg dexamethasone suppression test is already elevated in populations with insulin resistance, PCOS, and fatty liver disease, making untargeted testing particularly prone to cascading unnecessary workups. Schumer’s case involved a specific iatrogenic etiology and is not representative of the typical patient self-diagnosing from a TikTok video. Applying Endocrine Society criteria to determine who actually warrants screening remains the appropriate clinical response when these patients present.